These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 25727954)

  • 1. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus.
    Li H; Xu J; Fan X
    J Pharmacol Sci; 2015 Feb; 127(2):170-80. PubMed ID: 25727954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing.
    Fineman M; Flanagan S; Taylor K; Aisporna M; Shen LZ; Mace KF; Walsh B; Diamant M; Cirincione B; Kothare P; Li WI; MacConell L
    Clin Pharmacokinet; 2011 Jan; 50(1):65-74. PubMed ID: 21142268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration.
    Cirincione B; Edwards J; Mager DE
    AAPS J; 2017 Mar; 19(2):487-496. PubMed ID: 27896683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
    Henry RR; Logan D; Alessi T; Baron MA
    Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
    Wang Y; Xu B; Zhu L; Lou K; Chen Y; Zhao X; Wang Q; Xu L; Guo X; Ji L; Cui Y; Fang Y
    Clin Drug Investig; 2017 Dec; 37(12):1107-1115. PubMed ID: 28932995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once weekly exenatide: efficacy, tolerability and place in therapy.
    Wysham C; Grimm M; Chen S
    Diabetes Obes Metab; 2013 Oct; 15(10):871-81. PubMed ID: 23425609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans.
    Gao W; Jusko WJ
    Drug Metab Dispos; 2012 May; 40(5):990-7. PubMed ID: 22338110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.
    Hu M; Zhang Y; Xiang N; Zhong Y; Gong T; Zhang ZR; Fu Y
    Pharm Res; 2016 Jun; 33(6):1318-26. PubMed ID: 26857900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes.
    Iwamoto K; Nasu R; Yamamura A; Kothare PA; Mace K; Wolka AM; Linnebjerg H
    Endocr J; 2009; 56(8):951-62. PubMed ID: 19706990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
    Ryan GJ; Moniri NH; Smiley DD
    Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
    Trautmann ME; Han J; Ruggles J
    Clin Ther; 2016 Jun; 38(6):1464-1473. PubMed ID: 27126504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
    Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
    Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus.
    Cui YM; Guo XH; Zhang DM; Tham LS; Tang CC; Mace K; Linnebjerg H
    J Diabetes; 2013 Jun; 5(2):127-35. PubMed ID: 23332026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is insulin the most effective injectable antihyperglycaemic therapy?
    Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
    Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
    Gu N; Cho SH; Kim J; Shin D; Seol E; Lee H; Lim KS; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2014 Jan; 36(1):101-14. PubMed ID: 24373998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.